Perrigo Company PLC (PRGO): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Perrigo Company ( PRGO) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.1%. By the end of trading, Perrigo Company fell $6.79 (-4.4%) to $146.49 on heavy volume. Throughout the day, 3,762,324 shares of Perrigo Company exchanged hands as compared to its average daily volume of 1,288,100 shares. The stock ranged in price between $144.46-$155.22 after having opened the day at $153.87 as compared to the previous trading day's close of $153.28. Other companies within the Drugs industry that declined today were: Oramed Pharmaceuticals ( ORMP), down 13.8%, DARA Biosciences ( DARA), down 13.8%, GW Pharmaceuticals ( GWPH), down 9.4% and Pernix Therapeutics Holdings ( PTX), down 9.3%.

Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Perrigo Company has a market cap of $14.7 billion and is part of the health care sector. Shares are down 0.1% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Perrigo Company a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Perrigo Company as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front, Prima Biomed ( PBMD), up 45.3%, Repros Therapeutics ( RPRX), up 15.8%, Reliv' International ( RELV), up 11.1% and Can Fite Biofarma ( CANF), up 10.2% , were all gainers within the drugs industry with Johnson & Johnson ( JNJ) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

McDonald's Takes Bite Out of Dow, but Nasdaq and S&P 500 at Records

Perrigo Stock Jumps as Starboard's Smith Says Generic Drugs a Strong Business

Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain

These Stocks Have Changed Direction

Stocks Tank as Trump, North Korea Exchange Barbs